Joomla gallery extension by joomlashine.com
Main Promo Images
Latest news on Friedreich's Ataxia research
Updated results from clinical trials and research initiatives
Friedreich's Ataxia fundraising activities and staying in touch
Participate and stay informed about our fundraising events. Take part in our Facebook community with FA patients, relatives, researchers and friends from all around the world!
Studies with non-human primates have made major contributions to our understanding of the brain and will continue to be an important, if small, part of neuroscience research, according to a recent review published in the British medical journal, The Lancet.
Authors John P. Capitanio, professor of psychology at UC Davis and associate director of the California National Primate Research Center, and Professor Marina E. Emborg at the University of Wisconsin-Madison and the Wisconsin National Primate Research Center describe the importance of non-human primates in studies of Alzheimer's disease, Parkinson's disease, neurological complications of AIDS and stress.
"The key contribution of these studies is based on the similarities between the brains of humans and those of non-human primates," said Capitanio, who studies animal behavior . Human and monkey brains show similar organization and structure, and the animals show complex behavior that can be compared to human behavior. However, he said, several complicating factors will always limit the number of animals used, including the financial expense, ethical issues and the relative difficulty of breeding compared to other model animals such as rodents.
All animal models have their strengths and limitations, Capitanio said. But just as a model building helps engineers and architects understand how a structure will work, animal models can help researchers understand body systems.
For example, the drug MPTP -- first synthesized in an illegal drug laboratory -- causes symptoms similar to Parkinson's disease in both humans and monkeys, but not in rats or mice, which lack a crucial enzyme. Researchers are now studying monkeys treated with MPTP to better understand new treatments for Parkinson's disease -- the second most common neurodegenerative disease in people over 65.
"A model is not the real thing, but it can help you understand the real thing," Capitanio said.
The California National Primate Research Center (CNPRC) is part of a network of eight national primate research centers sponsored by the National Center for Research Resources, a division of the National Institutes of Health.
On the Net:
California National Primate Research Center
If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.
The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.
Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!
Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:
1) Gene Therapy for Friedreich's Ataxia research project:
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.
The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.